TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17303529

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 15879354

Group type: EXPERIMENTAL
Intervention: Continuous methimazole (MMI) treatment
Number of subjects: 504

Group type: COMPARATOR
Intervention: Radioiodine treatment
Number of subjects: 504
Study: 14704751

Group type: EXPERIMENTAL
Intervention: Unilateral inferior oblique muscle myectomy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard recession for inferior oblique muscle overaction
Number of subjects: 24
Study: 10658521

Group type: EXPERIMENTAL
Intervention: Extended mastectomy with internal mammary node dissection
Number of subjects: 737

Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 737
Study: 8876348

Group type: EXPERIMENTAL
Intervention: Diet combined with resistance training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diet only (3,400 kJ/day)
Number of subjects: 20
Study: 2065721

Group type: EXPERIMENTAL
Intervention: 20 mg ketanserin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7158619

Group type: EXPERIMENTAL
Intervention: Assertiveness training
Number of subjects: 343

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 343

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 343
Study: 31644605

Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine
Number of subjects: 613
Study: 28601335

Group type: EXPERIMENTAL
Intervention: Take-home box trainer (BT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Virtual reality simulator (VR)
Number of subjects: 25
Study: 27023009

Group type: EXPERIMENTAL
Intervention: Otelixizumab (anti-CD3 monoclonal antibody) administered subcutaneously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis measures
Number of subjects: 0
Study: 25062593

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 50
Study: 22429859

Group type: EXPERIMENTAL
Intervention: Irrigated gold tip catheter
Number of subjects: 60

Group type: COMPARATOR
Intervention: Irrigated platinum tip catheter
Number of subjects: 60
Study: 19369188

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 11

Group type: COMPARATOR
Intervention: Park sham device
Number of subjects: 11
Study: 18204132

Group type: EXPERIMENTAL
Intervention: Extra-fine HFA beclomethasone dipropionate (HFA-BDP) 400 microg twice daily for 7 days followed by 200 microg twice daily for 4 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 15785378

Group type: EXPERIMENTAL
Intervention: Candesartan treatment for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 individuals after renal donation)
Number of subjects: 20
Study: 12218749

Group type: EXPERIMENTAL
Intervention: 4-month whole body vibration training (4 min/day, 3-5 times a week)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 9858270

Group type: EXPERIMENTAL
Intervention: Brenner tumors on T2-weighted images
Number of subjects: 21

Group type: COMPARATOR
Intervention: Other ovarian tumors on T2-weighted images
Number of subjects: 21
Study: 8585887

Group type: EXPERIMENTAL
Intervention: Single 30 mg dose of Centchroman (group I, n = 8)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 30 mg Centchroman twice a week for twelve weeks (group II, n = 5)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both dosing groups (group I and group II)
Number of subjects: 13
Study: 2162275

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (IV infusion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Peptide histidine valine (IV infusion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Peptide histidine methionine (IV infusion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (intra-arterial infusion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Peptide histidine valine (intra-arterial infusion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide, peptide histidine methionine, peptide histidine valine (IV infusion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Peptide histidine valine
Number of subjects: 6
Study: 375053

Group type: EXPERIMENTAL
Intervention: Cyclic vincristine‐streptonigrin alternating every 2 weeks with cyclophosphamide‐prednisone up to 155 days
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Sequential treatment with the same 4 drugs taken singly up to 182 days
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Vincristine‐prednisone induction for 6 weeks followed by cyclophosphamide maintenance
Number of subjects: 203
Study: 30999125

Group type: EXPERIMENTAL
Intervention: Exercise and MFGM (Ex + MFGM)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Exercise and placebo (Ex + P)
Number of subjects: 126

Group type: COMPARATOR
Intervention: MFGM
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 28372652

Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 25936547

Group type: EXPERIMENTAL
Intervention: Web-based supportive intervention facilitated by a nurse
Number of subjects: 36
Study: 23494802

Group type: EXPERIMENTAL
Intervention: Curcuminoids (1 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21338986

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 80
Study: 19720791

Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% fat, 60% carbohydrate)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-carbohydrate diet (60% fat, 20% carbohydrate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-carbohydrate diet
Number of subjects: 24
Study: 17230585

Group type: EXPERIMENTAL
Intervention: Oat beta-glucan enriched fecal water
Number of subjects: 6
Study: 15182511

Group type: EXPERIMENTAL
Intervention: Oxygen enriched air (24.30 +/- 0.88% oxygen)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 12
Study: 11843243

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 797

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 797
Study: 9777083

Group type: EXPERIMENTAL
Intervention: Caudal morphine 25 micrograms.kg‐1
Number of subjects: 52

Group type: COMPARATOR
Intervention: Caudal morphine 50 micrograms.kg‐1
Number of subjects: 52
Study: 7889959

Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg q. 12 hours
Number of subjects: 702

Group type: COMPARATOR
Intervention: Cefaclor 500 mg q. eight hours
Number of subjects: 702

Group type: COMPARATOR
Intervention: Cefuroxime axetil 500 mg q. 12 hours
Number of subjects: 702

Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate 500 mg q. eight hours
Number of subjects: 702
Study: 3323023

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29595510

Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE (10 μg ID93 + 2 μg GLA-SE)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE (2 μg ID93 + 2 μg GLA-SE)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE (10 μg ID93 + 5 μg GLA-SE)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 66
Study: 27709734

Group type: EXPERIMENTAL
Intervention: E-health intervention for siblings
Number of subjects: 12
Study: 25704662

Group type: EXPERIMENTAL
Intervention: Balloon colonoscopy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 126
Study: 23906657

Group type: EXPERIMENTAL
Intervention: Gum chewing (sugarless gum, chewed three times for 30 min each from the first postoperative morning until the first passage of flatus)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 149
Study: 20951018

Group type: EXPERIMENTAL
Intervention: COPE-active programme (6-month compulsory period: 3 sessions/week; 5-month optional period: 2 sessions/week)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: COPE-active programme
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 153
Study: 18510625

Group type: EXPERIMENTAL
Intervention: 1-day oral sodium phosphate solution (NaP solution) (1 mL/kg/day, maximum 90 mL in two divided doses; regimen A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 3-day magnesium citrate (4 mL/kg/day x 3 days, maximum 237 mL, followed by an enema; regimen B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1-day oral sodium phosphate solution (NaP solution) (regimen A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 3-day magnesium citrate (regimen B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 48
Study: 16779923

Group type: EXPERIMENTAL
Intervention: Early-pubertal (EP) males
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mid-pubertal (MP) males
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late-pubertal (LP) males
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young-adult (YA) males
Number of subjects: 0
Study: 14632796

Group type: EXPERIMENTAL
Intervention: Evidence-based treatment guidelines for pemphigus vulgaris
Number of subjects: 0
Study: 14719289

Group type: EXPERIMENTAL
Intervention: Compound Oldenlandis Mixture
Number of subjects: 86

Group type: COMPARATOR
Intervention: Dang Gui Ku Shen Wan (Control)
Number of subjects: 86
Study: 10220209

Group type: EXPERIMENTAL
Intervention: Digital imaging technique
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 18
Study: 8615060

Group type: EXPERIMENTAL
Intervention: Calcipotriol treatment for 6 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Calcipotriol treatment
Number of subjects: 26
Study: 2671058

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 1091149

Group type: EXPERIMENTAL
Intervention: Short-term antibiotic prophylaxis regimen with 3 Gm. of cephaloridine in divided doses on the day of operation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Long-term antibiotic prophylaxis regimen with oral cephalexin postoperatively
Number of subjects: 100
Study: 31754826

Group type: EXPERIMENTAL
Intervention: Scheimpflug camera (Pentacam)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Anterior segment optical coherence tomography (AS-OCT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ultrasound pachymetry (USP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of devices in < 600 μm group
Number of subjects: 44
Study: 27882592

Group type: EXPERIMENTAL
Intervention: Ureteroscopic stone surgery with JJ catheterisation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (healthy males)
Number of subjects: 72
Study: 25826715

Group type: EXPERIMENTAL
Intervention: Patient Safety Screener-2
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Patient Safety Screener-3
Number of subjects: 951

Group type: COMPARATOR
Intervention: Beck Scale for Suicide Ideation (BSSI)
Number of subjects: 951
Study: 23673884

Group type: EXPERIMENTAL
Intervention: HIV intervention
Number of subjects: 848
Study: 21842168

Group type: EXPERIMENTAL
Intervention: EEG neurofeedback (NF)
Number of subjects: 35

Group type: COMPARATOR
Intervention: EMG biofeedback (BF)
Number of subjects: 35
Study: 19380134

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) abciximab administration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous (IV) abciximab administration
Number of subjects: 50
Study: 18389773

Group type: EXPERIMENTAL
Intervention: Special diet consisting of 15 ml/day balsamic vinegar from apples and honey, seabuckthorn berry, rosemary, sage, and basil extracts, 150 g/day whole wheat bread with 2.5% VITAPAN, 15 ml/day grape seed extract rich in polyphenols (gr. 1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (gr. 2)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Special diet (gr. 1)
Number of subjects: 34
Study: 15336619

Group type: EXPERIMENTAL
Intervention: 5 mg of alendronate daily + exercise (Al+Ex+)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 5 mg alendronate daily (Al+Ex‐)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo + exercise (Al‐Ex+)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (Al‐Ex‐)
Number of subjects: 102
Study: 11519552

Group type: EXPERIMENTAL
Intervention: Barium suspension with dynamic viscosity of 320 cPs (G1)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Barium suspension with dynamic viscosity of 2500 cPs (G2)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Barium suspension with dynamic viscosity of 3200 cPs (G3)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (CG) with standard barium suspension viscosity of 280 cPs
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Sodium members in paired groups
Number of subjects: 161
Study: 9781930

Group type: EXPERIMENTAL
Intervention: Perindopril, 4 mg o.d. for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Losartan, 50 mg o.d. for 6 weeks
Number of subjects: 28
Study: 7828343

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (5 micrograms/kg/min i.v.) for 83-296 hours
Number of subjects: 9
Study: 3280759

Group type: EXPERIMENTAL
Intervention: Lateral posterior approach to the ilium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lateral anterior approach to the ilium
Number of subjects: 100
Study: 31839368

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bupivacaine HCl
Number of subjects: 52
Study: 31162530

Group type: EXPERIMENTAL
Intervention: Dry-weight reduction guided by lung ultrasound
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard-of-care treatment (control)
Number of subjects: 71
Study: 27771359

Group type: EXPERIMENTAL
Intervention: Active IFC + Pilates
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo IFC + Pilates
Number of subjects: 148
Study: 26261007

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir (n=25)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir with ribavirin (n=26)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir with ribavirin (n=50)
Number of subjects: 126
Study: 23421578

Group type: EXPERIMENTAL
Intervention: Nursing intervention program using abdominal palpation of Leopold's Maneuvers
Number of subjects: 108

Group type: COMPARATOR
Intervention: Ordinary health-related advice
Number of subjects: 108
Study: 20837369

Group type: EXPERIMENTAL
Intervention: Aleglitazar (600 μg/day)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 174
Study: 19269691

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Escitalopram and Nortriptyline
Number of subjects: 797
Study: 16954961

Group type: EXPERIMENTAL
Intervention: Whey-predominant study formula (protein/energy ratio: 1.8 g/100 kcal)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional casein-predominant formula (protein/energy ratio: 2.6 g/100 kcal)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Whey-predominant study formula
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional casein-predominant formula
Number of subjects: 162
Study: 14707568

Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (NMBA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional therapy without NMBA (Control group)
Number of subjects: 56
Study: 11343407

Group type: EXPERIMENTAL
Intervention: Activities with maintained action results during the activity and perceptually preserved in the end product; cue conditions: verbal, object, action, and reenactment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activities where action results disappeared from view during the activity and were transformed within the end product; cue conditions: verbal, object, action, and reenactment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Picture supports provided during activities for 5‐ and 7‐year‐olds.
Number of subjects: 0
Study: 8970933

Group type: EXPERIMENTAL
Intervention: Alprostadil (125, 250, 500, and 1000 microg)
Number of subjects: 1511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1511

Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 1511
Study: 7965783

Group type: EXPERIMENTAL
Intervention: Tandospirone citrate (40, 80 and 160 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5, 1.0 and 2.0 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2888691

Group type: EXPERIMENTAL
Intervention: Intracapsular extraction with contact lens fitting
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Intraocular implants after intracapsular and extracapsular extraction
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Overall surgery (both treatment modes)
Number of subjects: 327
Study: 31786829

Group type: EXPERIMENTAL
Intervention: Automated office blood pressure measurement without preceding rest
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Automated office blood pressure measurement with 5 minutes of preceding rest
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Automated office blood pressure measurement without preceding rest as the first measurement
Number of subjects: 100
Study: 29797670

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (TD group)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Imiquimod 5% cream (FTF group)
Number of subjects: 157
Study: 28823947

Group type: EXPERIMENTAL
Intervention: GSK2269557 1000 μg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: GSK2269557 (various doses: 100, 200, 500, 700, 1000, 2000 μg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 25974776

Group type: EXPERIMENTAL
Intervention: Nasal suction technique and ultrasonic surgery approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional technique with rotary instruments (control)
Number of subjects: 30
Study: 23633445

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study: 20959857

Group type: EXPERIMENTAL
Intervention: Oolong tea
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oolong tea with added catechins
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oolong tea with added oolong tea polyphenols
Number of subjects: 19

Group type: COMPARATOR
Intervention: Caffeinated water
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unsupplemented water
Number of subjects: 19
Study: 17484511

Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/30 microg ethinyl estradiol (EE)
Number of subjects: 91

Group type: COMPARATOR
Intervention: 2 mg cyproterone acetate (CPA)/35 microg EE
Number of subjects: 91
Study: 15315115

Group type: EXPERIMENTAL
Intervention: Early feeding with human milk (enteral trophic nutrition) and fortified with human milk fortifier
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not fed early with human milk and not given human milk fortifier)
Number of subjects: 100
Study: 11593127

Group type: COMPARATOR
Intervention: Infant formula (group M, n = 56)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Yogurt (group Y, n = 56)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Yogurt (group Y) in children with reducing sugars in stools
Number of subjects: 112

Group type: COMPARATOR
Intervention: Infant formula (group M) in children with reducing sugars in stools
Number of subjects: 112
Study: 9638309

Group type: EXPERIMENTAL
Intervention: Oral administration of Tramal drops (100 mg tramadol-HCl)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous injection of tramadol (100 mg tramadol-HCl)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral administration of Tramal drops
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous injection of tramadol
Number of subjects: 8
Study: 7974587

Group type: EXPERIMENTAL
Intervention: CC method of measuring carotid stenosis
Number of subjects: 1001

Group type: COMPARATOR
Intervention: ECST method of measuring carotid stenosis
Number of subjects: 1001

Group type: COMPARATOR
Intervention: NASCET method of measuring carotid stenosis
Number of subjects: 1001
Study: 2592585

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31038698

Group type: EXPERIMENTAL
Intervention: Bothersome lower urinary tract symptoms (incontinence)
Number of subjects: 23240

Group type: EXPERIMENTAL
Intervention: Bothersome lower urinary tract symptoms (nocturia)
Number of subjects: 23240

Group type: COMPARATOR
Intervention: Age group comparison
Number of subjects: 23240

Group type: COMPARATOR
Intervention: Different urological symptoms
Number of subjects: 23240
Study: 29951768

Group type: EXPERIMENTAL
Intervention: Acute cocoa flavanols (530 mg CF, 100 mg epicatechin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26808137

Group type: EXPERIMENTAL
Intervention: Low-dose/intensity regimen of behavior modification (large-group parent training)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Low dose of stimulant medication
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Low-intensity behavior modification
Number of subjects: 146
Study: 25198196

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vemurafenib followed by ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 0